|
Synonyms: BL-B01D1 | BMS-986507 | BMS986507 | Iza-bren®
izalontamab brengitecan is an approved drug
Compound class:
Antibody
Comment: Izalontamab brengitecan (BL-B01D1) is a first-in-class bispecific antibody-drug conjugate (ADC) that is designed to deliver the camptothecin derived topoisomerase I inhibitor Ed-04 payload to tumour cells that express EGFR and HER3 receptor tyrosine kinases. The drug carries of eight toxin molecules per antibody (SI-B001) molecule [7,9]. Peptide sequences for the heavy and light chains of the parental antibody (obtained from the INN record) are claimed in patent US10919977, specifically for the clone named SI-1X6.4 [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Bian X, Yang T, Yin H, Hu B, Yao K, Jiang S, Chen Y, Lin J, Cao M, Liu N et al.. (2025)
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. J Clin Oncol, 43 (32): 3505-3515. [PMID:41061200] |
|
2. Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y et al.. (2026)
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. J Clin Invest, 136 (11). [PMID:41945392] |
|
3. Gao Z, Tan P, Kovacevich BR, Renshaw BR, Adamo JB, Mak NSA, Zhuo S, Chen L, Zhu Y. (2021)
Bispecific tetravalent antibodies and methods of making and using thereof. Patent number: US10919977B2. Assignee: Sichuan Baili Pharmaceutical Co Ltd, Systimmune Inc. Priority date: 19/12/2015. Publication date: 16/02/2021. |
|
4. Hong SD, Wang YS, Zhao HY, Zhao YY, Wang QM, Ma YX, Li YS, Huang Y, Yang YP, Fu ZM et al.. (2026)
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol, 37 (6): 813-824. [PMID:41611210] |
|
5. Liu C, Liu D, Ji Y, Sun M, Gao S, Ma X, Zhong D, Zhu J, Cao Y, Qi C et al.. (2025)
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med, 31 (10): 3485-3491. [PMID:40640393] |
|
6. Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, Fang W, Guo Y, Han Y, Yang K et al.. (2024)
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol, 25 (7): 901-911. [PMID:38823410] |
|
7. Wan W, Zhao S, Zhou S, Zhang Y, Chen L, Li G, Renshaw B, Khalili JS, Xiao S, Zhu Y. (2023)
Abstract 2642: BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res, 83 (7_Supplement): 2642. DOI: 10.1158/1538-7445.AM2023-2642 |
|
8. Xue J, Kong D, Yao Y, Yang L, Yao Q, Zhu Y, Ding Y, Yang F, Gong J, Shen L et al.. (2020)
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. J Pharm Sci, 109 (10): 3172-3180. [PMID:32565357] |
|
9. Xue J, Ma Y, Zhao Y, Wang Y, Hong W, Huang Y, Yang Y, Fang W, Hong S, Zhang Y et al.. (2025)
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study. Clin Cancer Res, 31 (21): 4438-4445. [PMID:40260627] |
|
10. Yang Y, Zhou H, Tang L, Qiu S, Han Y, Ji D, Chen X, Lei F, Qu S, Deng B et al.. (2025)
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. Lancet, 406 (10516): 2235-2243. [PMID:41125110] |